How does ClinicalTrials.gov Impact Company Innovation?

Yazhou Niu

Papers from arXiv.org

Abstract: Pharmaceutical companies may have incentives to exaggerate the therapeutic effects of their developed products during the clinical stage, which endangers the health of patients. To increase transparency in clinical practice, the NIH established ClinicalTrials.gov in 2000, which indicates a significant impact on medicine. However, little evidence shows how ClinicalTrials.gov affects medical enterprises innovation. By identifying the patent application activities through USPTO, Pubmed, and Compustat, we used coherent DID to prove the impact of ClinicalTrials.gov on innovation. We found that the emergence of ClinicalTrials.gov reduced the number of patent applications and led to a shift in RD directions. This effect can also be moderated depending on firm size, probably because small companies are more incentivized to manipulate data. Hence, we suggest agencies could consider wide-ranging influences when formulating open science policies.

Date: 2024-05
References: View references in EconPapers View complete reference list from CitEc
Citations:

Published in 2024 STI conference

Downloads: (external link)
http://arxiv.org/pdf/2405.07998 Latest version (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:arx:papers:2405.07998

Access Statistics for this paper

More papers in Papers from arXiv.org
Bibliographic data for series maintained by arXiv administrators (help@arxiv.org).